NASDAQ:ANIX Anixa Biosciences (ANIX) Stock Price, News & Analysis $3.17 +0.14 (+4.62%) As of 11/6/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Anixa Biosciences Stock (NASDAQ:ANIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Anixa Biosciences alerts:Sign Up Key Stats Today's Range$2.99▼$3.1850-Day Range$2.60▼$3.4852-Week Range$2.32▼$5.46Volume121,638 shsAverage Volume203,242 shsMarket Capitalization$110.19 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. The company’s programs are designed to use the immune system to identify and attack disease-associated targets. Anixa’s oncology pipeline has included a chimeric antigen receptor T-cell (CAR-T) therapy targeting the follicle-stimulating hormone receptor, which is being investigated as a potential treatment for ovarian cancer and other cancers. The company has also been developing a preventive breast cancer vaccine designed to target alpha-lactalbumin, a protein associated with certain breast cancers. These programs have been advanced through collaborations with research and medical institutions, including Cleveland Clinic. Based in San Jose, California, Anixa Biosciences serves the biotechnology and healthcare markets through research collaborations and the development of potential therapeutic products. The company was formerly known as ITUS Corporation and adopted the Anixa Biosciences name in 2018. Amit Kumar serves as the company’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Anixa Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreANIX MarketRank™: 3.734915254235 of 5 starsAnixa Biosciences scored higher than 75% of companies evaluated by MarketBeat, and ranked 141st out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingAnixa Biosciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAnixa Biosciences has a consensus price target of $8.00, representing about 152.4% upside from its current price of $3.17.Amount of Analyst CoverageAnixa Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Anixa Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Anixa Biosciences are expected to remain at ($0.31) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anixa Biosciences is -9.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anixa Biosciences is -9.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnixa Biosciences has a P/B Ratio of 7.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Anixa Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.49% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 6.39.Change versus previous monthShort interest in Anixa Biosciences has recently increased by 23.08%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnixa Biosciences does not currently pay a dividend.Dividend GrowthAnixa Biosciences does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.75 News SentimentAnixa Biosciences has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Anixa Biosciences this week, compared to 3 articles on an average week.Search Interest10 people have searched for ANIX on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.MarketBeat Follows8 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days. Company Ownership4.6 / 5Insider TradingAcquiring Shares Cluster Insider Buying4 insiders have purchased shares of Anixa Biosciences in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $291,587.00 in company stock, which represents 0.2646% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Anixa Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $291,587.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders26.40% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions29.13% of the stock of Anixa Biosciences is held by institutions.Read more about Anixa Biosciences' insider trading history. Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIX Stock News HeadlinesAnixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026November 4 at 8:35 AM | prnewswire.comAnixa Biosciences (NASDAQ:ANIX) CEO Acquires $15,850.00 in StockNovember 3, 2026 | insidertrades.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 7 at 1:00 AM | Behind the Markets (Ad)Anixa Biosciences (NASDAQ:ANIX) Stock Moved Down to "Sell" by Wall Street ZenOctober 31, 2026 | americanbankingnews.comAnixa Biosciences, Inc. Completes Dosing Of Fifth Cohort In Its Ongoing Phase 1 Clinical Trial Evaluating Its Novel FSHR-Targeted CAR-T Therapy For Recurrent Ovarian CancerOctober 28, 2026 | marketscreener.comMAnixa Biosciences (NASDAQ:ANIX) Director Lewis Titterton, Jr. Acquires 8,000 Shares of Company StockOctober 27, 2026 | americanbankingnews.comInsider Buying: Anixa Biosciences (NASDAQ:ANIX) Director Purchases 8,000 Shares of StockOctober 27, 2026 | insidertrades.comInsider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Acquires 8,000 Shares of StockOctober 23, 2026 | insidertrades.comSee More Headlines ANIX Stock Analysis - Frequently Asked Questions How have ANIX shares performed this year? Anixa Biosciences' stock was trading at $3.12 at the beginning of the year. Since then, ANIX shares have increased by 1.6% and is now trading at $3.17. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences Inc (NASDAQ:ANIX) posted its quarterly earnings data on Wednesday, September, 9th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.00. Who are Anixa Biosciences' major shareholders? Anixa Biosciences' top institutional shareholders include D.A. Davidson & CO. and CoreCap Advisors LLC (0.18%). Insiders that own company stock include Lewis H Titterton Jr, Amit Kumar, Arnold M Baskies and Michael Catelani. View institutional ownership trends. How do I buy shares of Anixa Biosciences? Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anixa Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anixa Biosciences investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Rocket One Inc. Common Stock (RKTO), Silo Pharma (SILO), Rocket Lab (RKLB) and Archer Aviation (ACHR). Company Calendar Last Earnings9/09/2026Today11/07/2026Next Earnings (Estimated)1/11/2027Fiscal Year End10/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ANIX's financial health is in the Green zone, according to TradeSmith. ANIX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ANIX CIK715446 Webwww.anixa.com Phone(408) 708-9808Fax631-549-5974Employees4Year Founded1982Price Target and Rating Average Price Target for Anixa Biosciences$8.00 High Price Target$10.00 Low Price Target$6.00 Potential Upside/Downside+152.4%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-76.59% Return on Assets-67.80% Debt Debt-to-Equity RatioN/A Current Ratio8.55 Quick Ratio8.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book7.55Miscellaneous Outstanding Shares34,760,000Free Float25,586,000Market Cap$110.19 million OptionableOptionable Beta0.47 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:ANIX) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...Behind the Markets | SponsoredThe IRS loophole Trump fought to preserve for retirees401(k) balances have reached record highs on a rising stock market and strong job growth. But traditional acco...American Hartford Gold | SponsoredThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredElon Musk… A Total Fraud?Jeff Brown, the former tech executive who picked Nvidia in 2016 before it surged as high as 37,800 percent, ju...Brownstone Research | SponsoredYour first step can stay on paperIncome Blueprint, created by Matt, helps traders find and evaluate options opportunities. In his walkthrough, ...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANIX Stock Alerts